Review discusses HPLC methods for analyzing anti-tubercular drugs, highlighting validation and analytical challenges.
Tuberculosis (TB) remains a major global health challenge, necessitating highly reliable analytical methods for the quantification of first-line and second-line anti-tubercular drugs (ATDs) in pharmaceuticals and biological matrices. High-Performance Liquid Chromatography (HPLC) continues to be the most widely applied technique for routine analysis due to its selectivity, sensitivity, and robustness. This review provides an extensive discussion on chromatographic principles, method development strategies, validation parameters, and analytical challenges associated with ATDs such as isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolones, linezolid, Bedaquiline, Delamanid, and Pretomanid. Detailed literature summaries, forced degradation considerations, and future prospects of green chromatography, AQbD, and hyphenated techniques are highlighted.
No takes yet. Share an insight, caveat, or question.
Gali Haritha1*, Shaik Naziya Fathima2, Arunabha Mallik3 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: